CBChirag Bakhai

Chirag Bakhai

*This is an algorithmically generated author record based on publicly available information.

Chirag Bakhai has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

    by Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, et al.

    Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practise Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587 826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age‐stratified analyses, uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged > 60, women, Black people and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.

  • Open Access

    Mismatch between Clinical Need and Uptake: Distributional Health Gains and Health Inequalities from SGLT2 Inhibitors in Type 2 Diabetes in England

    by Lesley Owen, Chirag Bakhai, Jonathan Wray, Muksit Rahman, James Hawkins, Daniel J. Cuthbertson, Patrick Muller

    Background: Health inequalities remain a major public health challenge in England, with people living in more deprived areas experiencing poorer outcomes. Although SGLT2 inhibitors (SGLT2i) are clinically and cost-effective for type 2 diabetes mellitus (T2DM) and related cardiovascular and renal conditions, little is known about how their health benefits are distributed across deprivation groups. We examined the distribution of health benefits associated with SGLT2i across deprivation and clinical subgroups, and the implications for health inequalities.Methods: We used data from a 2023 cross-sectional analysis of the Clinical Practice Research Datalink (CPRD), linked to Hospital Episodes Statistics (HES) and small-area deprivation data in England. T2DM prevalence and selected comorbidities and SGLT2i uptake were estimated across deprivation quintiles. A distributional cost-effectiveness analysis was used to estimate total and net health benefits (QALYs) and opportunity costs. Scenario analyses examined increased uptake and alternative distributions of opportunity costs.Findings: T2DM and associated comorbidities were more prevalent in more deprived areas across all subgroups. SGLT2i uptake varied modestly by deprivation but more substantially across clinical subgroups. SGLT2i generated positive net health benefits across all groups, with the largest gains accruing to more deprived populations, reflecting disease burden and baseline risk. Increasing uptake increased health gains, with similar distributional patterns across deprivation groups.Interpretation: SGLT2i generate substantial net health benefits across all deprivation groups, with the greatest gains in more deprived populations. Improving uptake represents an important opportunity to improve population health while reducing health inequalities.

  • Open Access

    SGLT2 inhibitor use in type 2 diabetes in England: a population-based cross-sectional study of uptake of NICE guidance

    by Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, et al.

    Aims: An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication. Materials and Methods: Observational cohort study using Clinical Practice Research Data Link records linked to hospital admissions. Presence of a current prescription for an SGLT2 inhibitor was evaluated in people with T2DM on 1 st September 2023, stratified by CVD category (CVD only; HF only; both; high CVD risk; low CVD risk) and chronic kidney disease status, and by age, gender, ethnicity, deprivation, and T2DM duration. Adjusted associations between patient characteristics and uptake were evaluated using logistic regression. Results: In the cohort of 587,826 people with T2DM, the percentage with a current prescription was 19.5% for people with CVD, 29.4% for people with HF, 30.5% for people with both CVD and HF, and 19.9% and 20.2% respectively for people at high and low CVD risk. In age-stratified analyses uptake was higher in people with more comorbidities. In adjusted models, uptake was lower in people aged >60, women, Black people, and people living in areas of higher deprivation. Conclusions: Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake. Action is necessary to address inequalities by ethnicity and deprivation, and lower uptake for people with T2DM and CVD without HF.


  • Open Access

    Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study

    by Louisa J Ells, Tamara Brown, Jamie Matu, Ken Clare, Simon Rowlands, Maria Maynard, Karina Kinsella, Kevin Drew, Jordan R Marwood, Pooja Dhir, et al.

    Background: National Health Service England piloted a low-calorie diet programme, delivered through total diet replacement and behaviour change support via 1 : 1, group or digital delivery, to improve type 2 diabetes in adults with excess weight. Aim: To coproduce a qualitative and economic evaluation of the National Health Service low-calorie diet pilot, integrated with National Health Service data to provide an enhanced understanding of the long-term cost-effectiveness, implementation, equity and transferability across broad and diverse populations. Research questions: What are the theoretical principles, behaviour change components, content and mode of delivery of the programme, and is it delivered with fidelity to National Health Service specifications? What are the service provider, user and National Health Service staff experiences of the programme? Do sociodemographics influence programme access, uptake, compliance and success? What aspects of the service work and what do not work, for whom, in what context and why? Can the programme be improved to enhance patient experience and address inequities? What are the programme delivery costs, and policy implications for wide-spread adoption? Methods: A mixed-methods study underpinned by a realist-informed approach was delivered across five work packages, involving: semistructured interviews with service users (n = 67), National Health Service staff (n = 55), service providers (n = 9); 13 service provider focus groups; and service user surveys (n = 719). Findings were triangulated with clinical data from the National Health Service England’s first cohort analysis (n = 7540). Results: Fifty-five per cent of service users who started total diet replacement completed the programme and lost an average of 10.3 kg; 32% of those with data available to measure remission achieved it. Examination of programme mobilisation identified barriers around referral equality and the impact of COVID-19, while effective cross-stakeholder working and communication were key facilitators. Service delivery and fidelity assessments identified a drift in implementation fidelity, alongside variation in the behaviour change content across providers. Perceived barriers to programme uptake and engagement aligned across service providers and users, resulting in key learning on: the importance of person-centred care, service user support needs, improvements to total diet replacement and the social and cultural impact of the programme. Early National Health Service quantitative analyses suggest some socioeconomic variation in programme uptake, completion and outcomes. Insights from the evaluation and National Health Service data were combined to develop the programme theory and underpinning context, mechanisms and outcomes. These were used to develop a list of recommendations to improve the cultural competency of programme delivery, total diet replacement delivery, peer support and address psychological support needs. Cost-effectiveness analyses using short-term follow-up data indicated there is potential for the programme to be cost-effective, but not cost saving. Conclusions: The National Health Service low-calorie diet can provide a clinically effective and potentially cost-effective programme to support weight loss and glycaemic control in adults with type 2 diabetes. However, this evaluation identified areas for improvement in referral equity, uptake and completion, and fidelity of delivery, which have informed the development of the programme, which has now been rolled out nationally. Ongoing programme monitoring and long-term follow-up are now required. Future work and limitations: The real-world setting limited some data collection and analysis. Future work will focus on the analysis of long-term clinical and cost-effectiveness, and addressing inequalities. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR132075.